Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: An early closed randomized controlled trial

Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database

“…PORT had survival advantages in a randomized trial of adjuvant chemotherapy, in which the use of PORT was not randomized or mandatory [4], and in two population-based cohort studies, one using the National Cancer Data Base (NCDB) [5] and the other using the Surveillance, Epidemiology, and End Results (SEER) database [6]. On the other hand, in the randomized controlled trial conducted by Shen et al[10], PORT decreased the incidence of local recurrence and distant metastasis, but failed to improve overall survival (OS) when administered after complete resection of N2 NSCLCs. PORT also failed to improve OS, as well as failure-free survival, in the earlier study by Perry et al [11] on resected N2 NSCLC.…”

Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer

“…Despite improvements in radiotherapy delivery [1,2] and novel chemotherapy combinations and schemes [3,4], the median survival in this relatively heterogeneous collective population is $21 months with 3 year survival rates of $30% [5,6].…”

Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy

“…Despite slow accrual and a limited sample size of 140 patients, this study demonstrated improved local and regional control and improved distant disease free survival with POCRT. POCRT was also associated with a higher median survival (40 vs. 28 months) and although not statistically significant, the hazard ratio for death in the POCRT of 0.69 trended favorably (P=0.073) (12).…”

“…A recent randomized phase III study of patients with pN2 NSCLC evaluated treatment with either adjuvant chemotherapy alone versus concurrent chemotherapy followed by PORT (POCRT) (12). Despite slow accrual and a limited sample size of 140 patients, this study demonstrated improved local and regional control and improved distant disease free survival with POCRT.…”